Pharsight

1. List of Dhivy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033521	AVION PHARMS	Levodopa fractionated dose composition and use	Mar, 2039 (16 years from now)

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease; Method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG;100MG	TABLET;ORAL	Prescription

2. List of Rytary drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7094427	IMPAX LABS INC	Combination immediate release controlled release levodopa/carbidopa dosage forms	May, 2022 (8 months ago)
US8377474	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US8454998	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US8557283	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US9901640	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US9533046	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US9463246	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US9089608	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)
US9089607	IMPAX LABS INC	Controlled release formulations of levodopa and uses thereof	Dec, 2028 (5 years from now)

Market Authorisation Date: 07 January, 2015

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of post-encephalitic parkinsonism; Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Method of providing a therapeutically effective and stable median blood plasma level of levodopa

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
61.25 mg/245 mg	10 Jun, 2015	1		26 Dec, 2028	Non-Forfeiture
23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	24 Jun, 2015	1		26 Dec, 2028	Non-Forfeiture

Strength	Dosage	Availability
23.75MG;95MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
36.25MG;145MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
48.75MG;195MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
61.25MG;245MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription